08:59 AM EDT, 09/11/2025 (MT Newswires) -- Bausch Health ( BHC ) said Thursday it completed its $63 million take-private acquisition of Durect ( DRRX ) , adding the late-stage liver disease drug larsucosterol to its pipeline.

The company said the purchase was made through a tender offer of $1.75 a share in cash, with the deal also including potential milestone payments of up to $350 million tied to future net sales.

Bausch Health ( BHC ) said about 62% of Durect ( DRRX ) shares were validly tendered before the offer expired Sept. 10, after which its merger subsidiary combined with Durect ( DRRX ), making it a wholly owned unit.